ESC 2026: oral semaglutide shows lower 3-year CV risk than injectable in T2D
The analysis drew on the Epic Cosmos real-world database, encompassing 1,402,692 adults aged 40–75 years initiating oral or injectable semaglutide between January 2019 and January 2023.